Taletrectinib Expansion

Globally, NUVB is positioned to grow its IBTROZI footprint through a partnership with Eisai for taletrectinib, a ROS1‑positive lung‑cancer therapy. The UK MHRA has validated taletrectinib, creating a near‑term catalyst for international expansion, though the company faces execution and timing risks tied to global access and glioma trials. To fund these milestones, NUVB issued $250 million in convertible notes, enhancing liquidity at the cost of potential future dilution.